263 related articles for article (PubMed ID: 21985435)
1. Emerging therapeutic strategies to enhance HDL function.
Redondo S; Martínez-González J; Urraca C; Tejerina T
Lipids Health Dis; 2011 Oct; 10():175. PubMed ID: 21985435
[TBL] [Abstract][Full Text] [Related]
2. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
3. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.
Tuteja S; Rader DJ
Clin Pharmacol Ther; 2014 Jul; 96(1):48-56. PubMed ID: 24713591
[TBL] [Abstract][Full Text] [Related]
4. Reverse cholesterol transport in type 2 diabetes mellitus.
Tan KC
Diabetes Obes Metab; 2009 Jun; 11(6):534-43. PubMed ID: 19175378
[TBL] [Abstract][Full Text] [Related]
5. Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment.
Frambach SJCM; de Haas R; Smeitink JAM; Rongen GA; Russel FGM; Schirris TJJ
Pharmacol Rev; 2020 Jan; 72(1):152-190. PubMed ID: 31831519
[TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
7. Newer therapeutic strategies to alter high-density lipoprotein level and function.
Bosch N; Frishman WH
Cardiol Rev; 2014; 22(1):17-24. PubMed ID: 23707991
[TBL] [Abstract][Full Text] [Related]
8. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
9. HDL-targeted therapies: progress, failures and future.
Kingwell BA; Chapman MJ; Kontush A; Miller NE
Nat Rev Drug Discov; 2014 Jun; 13(6):445-64. PubMed ID: 24854407
[TBL] [Abstract][Full Text] [Related]
10. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
11. New horizons for cholesterol ester transfer protein inhibitors.
Schwartz GG
Curr Atheroscler Rep; 2012 Feb; 14(1):41-8. PubMed ID: 22083134
[TBL] [Abstract][Full Text] [Related]
12. [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].
Kleber ME; Grammer TB; März W
MMW Fortschr Med; 2010 Jul; 152 Suppl 2():47-55. PubMed ID: 21591319
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
14. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Sirtori CR
Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
Maïga SF; Kalopissis AD; Chabert M
Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
[TBL] [Abstract][Full Text] [Related]
16. Anacetrapib as a potential cardioprotective strategy.
Di Bartolo BA; Nicholls SJ
Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647
[TBL] [Abstract][Full Text] [Related]
17. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
Wu BJ; Shrestha S; Ong KL; Johns D; Dunn LL; Hou L; Barter PJ; Rye KA
Int J Cardiol; 2015 Nov; 199():204-12. PubMed ID: 26204569
[TBL] [Abstract][Full Text] [Related]
18. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of CETP inhibitors: a patent review.
Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D
Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255
[TBL] [Abstract][Full Text] [Related]
20. HDL therapy for the treatment of cardiovascular diseases.
Parolini C; Marchesi M; Chiesa G
Curr Vasc Pharmacol; 2009 Oct; 7(4):550-6. PubMed ID: 19485919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
